Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
BiotechTV - News
00:00
Durability and potential disease modification
Richard describes prolonged effects after drug clearance and suggests ITK inhibition may reset immunity.
Play episode from 07:45
Transcript
